PMID- 25349647
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141028
LR  - 20201001
IS  - 1948-5182 (Print)
IS  - 1948-5182 (Electronic)
VI  - 6
IP  - 10
DP  - 2014 Oct 27
TI  - Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy 
      in chronic HCV-genotype-1 patients: A meta-analysis.
PG  - 759-65
LID - 10.4254/wjh.v6.i10.759 [doi]
AB  - AIM: To investigate the predictability of interleukin-28B single nucleotide 
      polymorphism rs12979860 with respect to sustained virological response (SVR) in 
      chronically hepatitis C virus (HCV) genotype-1 patients treated with a 
      protease-inhibitor and pegylated interferon-alpha (Peg-INF-alpha) based triple-therapy. 
      METHODS: We searched PubMed, the Cochrane Library and Web of Knowledge for 
      studies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitor 
      based triple-therapy. Ten studies with 2707 patients were included into this 
      meta-analysis. We used regression methods in order to investigate determinants of 
      SVR. RESULTS: IL-28B-CC-genotype patients achieved higher SVR rates (odds 5.34, 
      95%CI: 3.81-7.49) than IL-28B-non-CC-genotype patients (1.88, 95%CI: 1.43-2.48) 
      receiving triple-therapy. The line of therapy (treatment-naive or -experienced 
      for Peg-INF-alpha) did not affect the predictive value of IL-28B (P = 0.1). 
      IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy 
      consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 
      3.38, 14.66, 7.84 and 2.91, respectively. The odds for CC genotype patients 
      treated with Faldaprevir cannot be quantified, as only a single study with a 100% 
      SVR rate was available. CONCLUSION: IL-28B-SNP predicts the outcome for chronic 
      HCV genotype-1 patients receiving protease inhibitor-based triple-therapy. The 
      predictive value varies between the different protease inhibitors.
FAU - Mechie, Nicolae-Catalin
AU  - Mechie NC
AD  - Nicolae-Catalin Mechie, Silke Cameron, Ahmad Amanzada, Department of 
      Gastroenterology and Endocrinology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
FAU - Rover, Christian
AU  - Rover C
AD  - Nicolae-Catalin Mechie, Silke Cameron, Ahmad Amanzada, Department of 
      Gastroenterology and Endocrinology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
FAU - Cameron, Silke
AU  - Cameron S
AD  - Nicolae-Catalin Mechie, Silke Cameron, Ahmad Amanzada, Department of 
      Gastroenterology and Endocrinology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
FAU - Amanzada, Ahmad
AU  - Amanzada A
AD  - Nicolae-Catalin Mechie, Silke Cameron, Ahmad Amanzada, Department of 
      Gastroenterology and Endocrinology, University Medical Center Goettingen, 
      Georg-August-University, 37075 Goettingen, Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Hepatol
JT  - World journal of hepatology
JID - 101532469
PMC - PMC4209421
OTO - NOTNLM
OT  - Direct antiviral agents
OT  - Hepatitis C virus
OT  - Interleukin 28B
OT  - Meta-analysis
OT  - Sustained virological response
EDAT- 2014/10/29 06:00
MHDA- 2014/10/29 06:01
PMCR- 2014/10/27
CRDT- 2014/10/29 06:00
PHST- 2014/06/06 00:00 [received]
PHST- 2014/07/29 00:00 [revised]
PHST- 2014/09/06 00:00 [accepted]
PHST- 2014/10/29 06:00 [entrez]
PHST- 2014/10/29 06:00 [pubmed]
PHST- 2014/10/29 06:01 [medline]
PHST- 2014/10/27 00:00 [pmc-release]
AID - 10.4254/wjh.v6.i10.759 [doi]
PST - ppublish
SO  - World J Hepatol. 2014 Oct 27;6(10):759-65. doi: 10.4254/wjh.v6.i10.759.